{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:19:29Z","timestamp":1783171169060,"version":"3.54.6"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004300","name":"Senior Talent Foundation of Jiangsu University","doi-asserted-by":"publisher","award":["5501290017"],"award-info":[{"award-number":["5501290017"]}],"id":[{"id":"10.13039\/501100004300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bmc.2026.118699","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:34:26Z","timestamp":1778340866000},"page":"118699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recent progress in small-molecule targeted therapies for melanoma treatment"],"prefix":"10.1016","volume":"139","author":[{"given":"Xinrui","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezhong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118699_bb0005","first-page":"704","article-title":"Recent changes and innovations in melanoma treatment: a review","volume":"11","author":"Sabag","year":"2020","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.bmc.2026.118699_bb0010","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/ph17020214","article-title":"A review of current and pipeline drugs for treatment of melanoma","volume":"17","author":"Natarelli","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bmc.2026.118699_bb0015","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/labinvest.2016.147","article-title":"Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features","volume":"97","author":"Merkel","year":"2017","journal-title":"Lab Investig"},{"key":"10.1016\/j.bmc.2026.118699_bb0020","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.3390\/cancers13174431","article-title":"Primary melanoma characteristics of metastatic disease: a Nationwide Cancer registry study","volume":"13","author":"Zhou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2026.118699_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115325","article-title":"Synthesis of thieno[3,2-e]pyrrolo[1,2-a]pyrimidine derivatives and their precursors containing 2-aminothiophenes fragments as anticancer agents for therapy of pulmonary metastatic melanoma","volume":"254","author":"Rogova","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0030","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3390\/ijms26051849","article-title":"Advances in melanoma and skin cancers","volume":"26","author":"Mallardo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118699_bb0035","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.3390\/ijms23073660","article-title":"Histone deacetylase (HDAC) inhibitors: a promising weapon to tackle therapy resistance in melanoma","volume":"23","author":"Palamaris","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118699_bb0040","doi-asserted-by":"crossref","first-page":"450","DOI":"10.6004\/jadpro.2022.13.4.7","article-title":"Encorafenib and Binimetinib combination therapy in metastatic melanoma","volume":"13","author":"Davis","year":"2022","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.26641","article-title":"Long-term survival in patients with advanced melanoma","volume":"7","author":"van Not","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bmc.2026.118699_bb0050","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11912-023-01385-6","article-title":"Chemotherapy in cutaneous melanoma: is there still a role?","volume":"25","author":"Pham","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.bmc.2026.118699_bb0055","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.3390\/cancers17162648","article-title":"Confronting melanoma Radioresistance: mechanisms and therapeutic strategies","volume":"17","author":"Gorodetska","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2026.118699_bb0060","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmc.2026.118699_bb0065","doi-asserted-by":"crossref","first-page":"9848","DOI":"10.3390\/ijms25189848","article-title":"Recent advancements in cell-based therapies in melanoma","volume":"25","author":"Nassief","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118699_bb0070","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00044-025-03515-0","article-title":"Small-molecule drug discovery in malignant melanoma: current status and prospective developments","volume":"35","author":"Miao","year":"2026","journal-title":"Med Chem Res"},{"key":"10.1016\/j.bmc.2026.118699_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100050","article-title":"A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(\u2606)","volume":"6","author":"Tarhini","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.bmc.2026.118699_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.1470","article-title":"1085P Ph I\/II study of PI3K-\u03b2 inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors","volume":"32","author":"Burton","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0085","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.3390\/cancers13215504","article-title":"A phase Ib study of Sotrastaurin, a PKC inhibitor, and Alpelisib, a PI3K\u03b1 inhibitor, in patients with metastatic uveal melanoma","volume":"13","author":"Shoushtari","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2026.118699_bb0090","doi-asserted-by":"crossref","first-page":"62","DOI":"10.21037\/cco.2018.06.08","article-title":"Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report","volume":"7","author":"Tang","year":"2018","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0095","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejca.2021.02.021","article-title":"Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway","volume":"148","author":"Mao","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmc.2026.118699_bb0100","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-1248","article-title":"A phase I study of the cyclin-dependent kinase 4\/6 inhibitor Ribociclib (LEE011) in patients with advanced solid tumors and lymphomas","volume":"22","author":"Infante","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118699_bb0105","doi-asserted-by":"crossref","first-page":"iv374","DOI":"10.1093\/annonc\/mdu344.2","article-title":"Phase Ib\/II study of LEE011 (CDK4\/6 inhibitor) and LGX818 (BRAF inhibitor) in BRAF-mutant melanoma","volume":"25","author":"Taylor","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0110","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1158\/1078-0432.CCR-21-3872","article-title":"Phase Ib\/II trial of Ribociclib in combination with Binimetinib in patients with NRAS-mutant melanoma","volume":"28","author":"Schuler","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118699_bb0115","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.bmc.2026.118699_bb0120","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/cncr.30663","article-title":"A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer research group (E2607)","volume":"123","author":"Kalinsky","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bmc.2026.118699_bb0125","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0130","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/annonc\/mdx079","article-title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","volume":"28","author":"Guo","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0135","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/s43018-024-00794-1","article-title":"Determinants of resistance and response to melanoma therapy","volume":"5","author":"Robertson","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.bmc.2026.118699_bb0140","doi-asserted-by":"crossref","first-page":"9666","DOI":"10.3390\/ijms24119666","article-title":"MAPK-ERK pathway","volume":"24","author":"Park","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118699_bb0145","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","article-title":"Melanoma","volume":"1","author":"Schadendorf","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bmc.2026.118699_bb0150","first-page":"1339","article-title":"UV-induced somatic mutations driving clonal evolution in healthy skin, nevus, and cutaneous melanoma","volume":"12","author":"Loras","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.bmc.2026.118699_bb0155","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2026.118699_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12081851","article-title":"Advances in melanoma: from genetic insights to therapeutic innovations","volume":"12","author":"Valdez-Salazar","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.bmc.2026.118699_bb0165","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/s41417-022-00437-6","article-title":"Targeting GNAQ\/11 through PKC inhibition in uveal melanoma","volume":"29","author":"Lietman","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.bmc.2026.118699_bb0170","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/neuonc\/noab159","article-title":"The PI3K\/Akt\/mTOR pathway as a preventive target in melanoma brain metastasis","volume":"24","author":"Tehranian","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bmc.2026.118699_bb0175","doi-asserted-by":"crossref","first-page":"1167930","DOI":"10.3389\/fonc.2023.1167930","article-title":"PI3K\/AKT\/mTOR pathway-derived risk score exhibits correlation with immune infiltration in uveal melanoma patients","volume":"13","author":"Geng","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0180","doi-asserted-by":"crossref","DOI":"10.1111\/pcmr.70054","article-title":"The roles of PTEN in melanoma suppression","volume":"38","author":"Parkman","year":"2025","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.bmc.2026.118699_bb0185","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/cancers12030742","article-title":"The role of PTEN loss in immune escape, melanoma prognosis and therapy response","volume":"12","author":"Cabrita","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2026.118699_bb0190","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140752","article-title":"Inhibiting the MNK1\/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses","volume":"131","author":"Huang","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmc.2026.118699_bb0195","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3390\/cells10061334","article-title":"CDK4\/6 inhibitors in melanoma: a comprehensive review","volume":"10","author":"Garutti","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bmc.2026.118699_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112531","article-title":"Getting under the skin: the role of CDK4\/6 in melanomas","volume":"204","author":"Guo","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0205","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2026.118699_bb0210","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1158\/1535-7163.MCT-20-1126","article-title":"Targeting CDK4\/6 represents a therapeutic vulnerability in acquired BRAF\/MEK inhibitor-resistant melanoma","volume":"20","author":"Nassar","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118699_bb0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13053-021-00178-x","article-title":"CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition","volume":"19","author":"Chan","year":"2021","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/j.bmc.2026.118699_bb0220","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1101\/gad.191999.112","article-title":"Melanoma: from mutations to medicine","volume":"26","author":"Tsao","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.bmc.2026.118699_bb0225","first-page":"2102","article-title":"MDM2\/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and immunotherapy","volume":"12","author":"Arnoff","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.bmc.2026.118699_bb0230","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/ijms24010065","article-title":"p53 family in resistance to targeted therapy of melanoma","volume":"24","author":"Vla\u0161i\u0107","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118699_bb0235","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1038\/sj.onc.1206461","article-title":"The INK4a\/ARF locus and melanoma","volume":"22","author":"Sharpless","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2026.118699_bb0240","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2026.118699_bb0245","doi-asserted-by":"crossref","first-page":"15262","DOI":"10.1038\/ncomms15262","article-title":"RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma","volume":"8","author":"Dorard","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2026.118699_bb0250","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1021\/acs.jmedchem.3c01830","article-title":"The discovery of Exarafenib (KIN-2787): overcoming the challenges of Pan-RAF kinase inhibition","volume":"67","author":"Chen","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0255","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.3390\/cancers15164026","article-title":"BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers","volume":"15","author":"Castellani","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2026.118699_bb0260","doi-asserted-by":"crossref","unstructured":"C. Zengarini, M. Mussi, G. Veronesi, A. Alessandrini, M. Lambertini, E. Dika, BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies, Clin Exp Dermatol, 47 (2022) 1131\u20131136.","DOI":"10.1111\/ced.15113"},{"key":"10.1016\/j.bmc.2026.118699_bb0265","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/CMR.0000000000000388","article-title":"Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma","volume":"27","author":"Li","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.bmc.2026.118699_bb0270","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.356","article-title":"Braf(V600E) cooperates with Pten loss to induce metastatic melanoma","volume":"41","author":"Dankort","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.bmc.2026.118699_bb0275","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1755-148X.2009.00578.x","article-title":"Frequent mutations in the MITF pathway in melanoma","volume":"22","author":"Cronin","year":"2009","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.bmc.2026.118699_bb0280","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1158\/2159-8290.CD-15-0896","article-title":"Oncogenic BRAF deletions that function as homodimers and are sensitive to inhibition by RAF dimer inhibitor LY3009120","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2026.118699_bb0285","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2217\/mmt-2017-0023","article-title":"Combating NRAS mutant melanoma: from bench to bedside","volume":"4","author":"Echevarr\u00eda-Vargas","year":"2017","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.bmc.2026.118699_bb0290","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bmc.2026.118699_bb0295","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1755-148X.2011.00873.x","article-title":"Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma","volume":"24","author":"Devitt","year":"2011","journal-title":"Pigm Cell Melanoma Res"},{"key":"10.1016\/j.bmc.2026.118699_bb0300","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jid.2018.12.033","article-title":"Molecular genomic profiling of melanocytic nevi","volume":"139","author":"Colebatch","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.bmc.2026.118699_bb0305","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3892\/ol.2022.13613","article-title":"Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma","volume":"25","author":"Zablocka","year":"2023","journal-title":"Oncol Lett"},{"key":"10.1016\/j.bmc.2026.118699_bb0310","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/2159-8290.CD-13-0017","article-title":"An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance","volume":"3","author":"Gibney","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2026.118699_bb0315","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/labinvest.2016.142","article-title":"The NF1 gene in tumor syndromes and melanoma","volume":"97","author":"Kiuru","year":"2017","journal-title":"Lab Investig"},{"key":"10.1016\/j.bmc.2026.118699_bb0320","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semcancer.2019.09.013","article-title":"The mutational landscape of mucosal melanoma","volume":"61","author":"Nassar","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.bmc.2026.118699_bb0325","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.3390\/cancers17223644","article-title":"KIT-mutant melanoma: understanding the pathway to personalized therapy","volume":"17","author":"Kaveti","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2026.118699_bb0330","doi-asserted-by":"crossref","first-page":"11322","DOI":"10.1038\/s41467-025-66428-x","article-title":"Early genetic evolution of driver mutations in uveal melanoma","volume":"16","author":"Dollar","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2026.118699_bb0335","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1535-7163.MCT-13-0499","article-title":"Crizotinib, a c-met inhibitor, prevents metastasis in a metastatic uveal melanoma model","volume":"12","author":"Surriga","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118699_bb0340","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/IAE.0b013e31824d09a8","article-title":"Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases","volume":"32","author":"Shields","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.bmc.2026.118699_bb0345","doi-asserted-by":"crossref","first-page":"2261278","DOI":"10.1080\/2162402X.2023.2261278","article-title":"Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patients","volume":"12","author":"Garc\u00eda-Mulero","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bmc.2026.118699_bb0350","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118699_bb0355","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrc3521","article-title":"The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer","volume":"13","author":"O\u2019Hayre","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2026.118699_bb0360","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2026.118699_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.100800","article-title":"Uveal melanoma: towards a molecular understanding","volume":"75","author":"Smit","year":"2020","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.bmc.2026.118699_bb0370","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bmc.2026.118699_bb0375","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","article-title":"Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases","volume":"123","author":"Yavuzyigitoglu","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bmc.2026.118699_bb0380","doi-asserted-by":"crossref","first-page":"1340408","DOI":"10.3389\/fonc.2024.1340408","article-title":"Multidisciplinary approach and treatment of acral and mucosal melanoma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0385","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s11912-023-01453-x","article-title":"Mucosal melanoma: epidemiology, clinical features, and treatment","volume":"25","author":"Sergi","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.bmc.2026.118699_bb0390","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/oncolo\/oyac091","article-title":"Management of Acral and Mucosal Melanoma: medical oncology perspective","volume":"27","author":"Jung","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.bmc.2026.118699_bb0395","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3390\/jcm9030690","article-title":"Immunohistochemical BRAF V600E expression and Intratumor BRAF V600E heterogeneity in Acral melanoma: implication in melanoma-specific survival","volume":"9","author":"Ito","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.bmc.2026.118699_bb0400","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/modpathol.2009.116","article-title":"Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous\/mucosal type","volume":"22","author":"Torres-Cabala","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bmc.2026.118699_bb0405","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10689-020-00209-x","article-title":"FRAMe: familial risk assessment of melanoma-a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma","volume":"20","author":"Holland","year":"2021","journal-title":"Fam Cancer"},{"key":"10.1016\/j.bmc.2026.118699_bb0410","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/biom10101447","article-title":"Genetic alterations in the INK4a\/ARF locus: effects on melanoma development and progression","volume":"10","author":"Ming","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmc.2026.118699_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104634","article-title":"Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib","volume":"299","author":"Tkacik","year":"2023","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0420","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2767-9764.CRC-24-0451","article-title":"Preclinical activity of the type II RAF inhibitor Tovorafenib in tumor models harboring either a BRAF fusion or an NF1 loss-of-function mutation","volume":"5","author":"Rastogi","year":"2025","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.bmc.2026.118699_bb0425","first-page":"774","article-title":"A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas","volume":"19","author":"Sun","year":"2017","journal-title":"Neuro-oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.681","article-title":"614MO type II RAF inhibitor tovorafenib in recurrent\/refractory (R\/R) melanoma or other solid tumors with RAF fusions and\/or RAF1 amplification","volume":"35","author":"Vieito","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0435","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1021\/acs.jmedchem.1c00230","article-title":"Discovery of new Imidazo[2,1-b]thiazole derivatives as potent Pan-RAF inhibitors with promising in vitro and in vivo anti-melanoma activity","volume":"64","author":"Abdel-Maksoud","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0440","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1158\/1078-0432.CCR-20-2563","article-title":"LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors","volume":"27","author":"Monaco","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118699_bb0445","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1021\/acs.jmedchem.9b00161","article-title":"Design and discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a selective, efficacious, and well-tolerated RAF inhibitor targeting RAS mutant cancers: the path to the clinic","volume":"63","author":"Ramurthy","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0450","doi-asserted-by":"crossref","unstructured":"A. Spira, V. Gambardella, S. Kato, C.B. Perez, M. Mckean, M.G. Cao, R. Kim, C.T. Chen, A. Italiano, P. Cassier, Abstract CT032: trials in progress: a global phase 1\/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma, Cancer Res, 83 (2023) CT032.","DOI":"10.1158\/1538-7445.AM2023-CT032"},{"key":"10.1016\/j.bmc.2026.118699_bb0455","doi-asserted-by":"crossref","first-page":"10897","DOI":"10.1021\/acs.jmedchem.9b01528","article-title":"Discovery of a first-in-class mitogen-activated protein kinase kinase 1\/2 degrader","volume":"62","author":"Wei","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0460","doi-asserted-by":"crossref","first-page":"15883","DOI":"10.1021\/acs.jmedchem.0c01609","article-title":"Potent and selective mitogen-activated protein kinase kinase 1\/2 (MEK1\/2) heterobifunctional small-molecule degraders","volume":"63","author":"Hu","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0465","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/acs.jmedchem.9b00810","article-title":"Design, synthesis, and biological evaluation of MEK PROTACs","volume":"63","author":"Vollmer","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0470","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1541-7786.MCR-17-0211","article-title":"BRAF-inhibitor associated MEK mutations increase RAF-dependent and -independent enzymatic activity","volume":"15","author":"Emery","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.bmc.2026.118699_bb0475","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/acs.jmedchem.1c02192","article-title":"Discovery of MAP855, an efficacious and selective MEK1\/2 inhibitor with an ATP-competitive mode of action","volume":"65","author":"Poddutoori","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0480","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.chembiol.2023.05.004","article-title":"Investigating the NRAS 5\u2019 UTR as a target for small molecules","volume":"30","author":"Balaratnam","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2026.118699_bb0485","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1021\/acs.jmedchem.3c00094","article-title":"Discovery of clinically used Octenidine as NRAS repressor that effectively inhibits NRAS-mutant melanoma","volume":"66","author":"Chen","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0490","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2025.02.001","article-title":"FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma","volume":"43","author":"Lubrano","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2026.118699_bb0495","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/2159-8290.CD-24-0139","article-title":"The Pan-RAF-MEK nondegrading molecular glue NST-628 is a potent and brain-penetrant inhibitor of the RAS-MAPK pathway with activity across diverse RAS- and RAF-driven cancers","volume":"14","author":"Ryan","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2026.118699_bb0500","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1039\/C9MD00269C","article-title":"BIM-46174 fragments as potential ligands of G proteins","volume":"10","author":"K\u00fcppers","year":"2019","journal-title":"MedChemComm"},{"key":"10.1016\/j.bmc.2026.118699_bb0505","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1021\/acs.jmedchem.0c01977","article-title":"Design, synthesis, and evaluation of small molecule g\u03b1q\/11 protein inhibitors for the treatment of uveal melanoma","volume":"64","author":"Ge","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0510","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.apsb.2022.04.016","article-title":"Discovery of small molecule g\u03b1q\/11 protein inhibitors against uveal melanoma","volume":"12","author":"Ge","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2026.118699_bb0515","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nchem.2577","article-title":"Total synthesis and structure-activity relationship studies of a series of selective G protein inhibitors","volume":"8","author":"Xiong","year":"2016","journal-title":"Nat Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0520","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2418398122","article-title":"Cyclic peptide inhibitors function as molecular glues to stabilize Gq\/11 heterotrimers","volume":"122","author":"M\u00fchle","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2026.118699_bb0525","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1158\/1078-0432.CCR-20-2860","article-title":"Combined inhibition of g\u03b1(q) and MEK enhances therapeutic efficacy in uveal melanoma","volume":"27","author":"Hitchman","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118699_bb0530","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1021\/jm901108b","article-title":"Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes","volume":"52","author":"Wagner","year":"2009","journal-title":"J Med Chem"},{"issue":"suppl.9030","key":"10.1016\/j.bmc.2026.118699_bb0535","article-title":"Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma","volume":"32","author":"Piperno-Neumann","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0540","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/1535-7163.MCT-19-0098","article-title":"Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071","volume":"19","author":"Piperno-Neumann","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118699_bb0545","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1021\/acs.jmedchem.3c02002","article-title":"Discovery of Darovasertib (NVP-LXS196), a Pan-PKC inhibitor for the treatment of metastatic uveal melanoma","volume":"67","author":"Visser","year":"2024","journal-title":"J Med Chem"},{"issue":"suppl.9510","key":"10.1016\/j.bmc.2026.118699_bb0550","article-title":"A phase 2 safety and efficacy study of neoadjuvant\/adjuvant darovasertib for localized ocular melanoma","volume":"42","author":"Joshua","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0555","article-title":"A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma","volume":"12","author":"Bauer","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2215","article-title":"1081O ctDNA reduction and clinical efficacy of the darovasertib+ crizotinib (daro+ crizo) combination in metastatic uveal melanoma (MUM)","volume":"34","author":"McKean","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0565","doi-asserted-by":"crossref","unstructured":"S.G. Jin, F. Padron, G.P. Pfeifer, UVA radiation, DNA damage, and melanoma, ACS Omega, 7 (2022) 32936\u201332948.","DOI":"10.1021\/acsomega.2c04424"},{"key":"10.1016\/j.bmc.2026.118699_bb0570","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s00432-021-03781-6","article-title":"The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors","volume":"148","author":"Kim","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0575","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41698-024-00684-w","article-title":"Efficacy of PARP inhibitor therapy after targeted BRAF\/MEK failure in advanced melanoma","volume":"8","author":"Phillipps","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114028","article-title":"Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function","volume":"157","author":"Li","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2026.118699_bb0585","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.3390\/cancers13184520","article-title":"PARP inhibitors in melanoma-an expanding therapeutic option?","volume":"13","author":"Chan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2026.118699_bb0590","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1158\/2767-9764.CRC-23-0101","article-title":"PARP inhibitors effectively reduce MAPK inhibitor resistant melanoma cell growth and synergize with MAPK inhibitors through a synthetic lethal interaction in vitro and in vivo","volume":"3","author":"Fr\u00f6hlich","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.bmc.2026.118699_bb0595","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a006129","article-title":"Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency","volume":"7","author":"Khaddour","year":"2021","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.bmc.2026.118699_bb0600","doi-asserted-by":"crossref","first-page":"688","DOI":"10.6004\/jnccn.2022.7102","article-title":"Determining PARP inhibition as a treatment strategy in melanoma based on homologous recombination deficiency-related loss of heterozygosity","volume":"21","author":"Zhou","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.bmc.2026.118699_bb0605","doi-asserted-by":"crossref","first-page":"S719","DOI":"10.1016\/j.annonc.2024.08.1155","article-title":"1087P phase II study of niraparib in patients with advanced melanoma with homologous recombination pathway gene mutations","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0610","article-title":"Phase II study of niraparib in patients with advanced melanoma with homologous recombination pathway gene mutations","volume":"9","author":"Kim","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0615","doi-asserted-by":"crossref","first-page":"10848","DOI":"10.1021\/acs.jmedchem.4c00296","article-title":"Novel bifunctional conjugates targeting PD-L1\/PARP7 as dual immunotherapy for potential Cancer treatment","volume":"67","author":"Gao","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0620","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/genes11050556","article-title":"Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological Actionability","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.bmc.2026.118699_bb0625","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.it.2019.02.004","article-title":"Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy","volume":"40","author":"Emran","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1016\/j.bmc.2026.118699_bb0630","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.3390\/cancers13194763","article-title":"Histone deacetylase (HDAC)-1, \u22122, \u22124, and \u22126 in uveal melanomas: associations with Clinicopathological parameters and patients\u2019 survival","volume":"13","author":"Levidou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2026.118699_bb0635","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-18-3382","article-title":"HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma","volume":"25","author":"Fai\u00e3o-Flores","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118699_bb0640","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e21527","article-title":"Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: an open-label, single-arm phase II study","volume":"42","author":"Mao","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0645","first-page":"A476","article-title":"797 significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-na\u00efve advanced melanoma (TN-Mel)","volume":"8","author":"Khushalani","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bmc.2026.118699_bb0650","article-title":"620 HBI-8000, a class I histone deacetylase (HDAC) inhibitor, in combination with nivolumab for treatment of anti-PD (L) 1-naive advanced melanoma: final analysis of study HBI-8000\u2013302","volume":"12","author":"Khushalani","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bmc.2026.118699_bb0655","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1021\/acs.jmedchem.1c01863","article-title":"Discovery of novel histone deacetylase 6 (HDAC6) inhibitors with enhanced antitumor immunity of anti-PD-L1 immunotherapy in melanoma","volume":"65","author":"Peng","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0660","doi-asserted-by":"crossref","first-page":"13067","DOI":"10.1021\/acs.jmedchem.4c01062","article-title":"Discovery of novel HDAC3 inhibitors with PD-L1 downregulating\/degrading and antitumor immune effects","volume":"67","author":"Sun","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0665","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1021\/acs.jmedchem.4c02445","article-title":"Discovery of highly potent and orally bioavailable histone deacetylase 3 inhibitors as Immunomodulators and enhancers of DNA-Damage response in Cancer therapy","volume":"68","author":"Li","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0670","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1021\/acs.jmedchem.4c02510","article-title":"Discovery of novel and highly potent dual PD-L1\/histone deacetylase 6 inhibitors with favorable pharmacokinetics for Cancer immunotherapy","volume":"68","author":"Hu","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0675","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1021\/acs.jmedchem.4c02529","article-title":"Discovery of dual PD-L1\/HDAC3 inhibitors for tumor immunotherapy","volume":"68","author":"Wang","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0680","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1021\/acs.jmedchem.4c02106","article-title":"Small-molecule modulators targeting coactivator-associated arginine methyltransferase 1 (CARM1) as therapeutic agents for Cancer treatment: current medicinal chemistry insights and emerging opportunities","volume":"68","author":"Li","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0685","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.ejca.2012.11.026","article-title":"Deregulation of protein methylation in melanoma","volume":"49","author":"Limm","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmc.2026.118699_bb0690","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1021\/acs.jmedchem.3c02265","article-title":"Development of (2-(Benzyloxy)phenyl)methanamine derivatives as potent and selective inhibitors of CARM1 for the treatment of melanoma","volume":"67","author":"Liu","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0695","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/2159-8290.CD-20-1144","article-title":"CARM1 inhibition enables immunotherapy of resistant tumors by dual action on tumor cells and T cells","volume":"11","author":"Kumar","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2026.118699_bb0700","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1021\/acs.jcim.1c01100","article-title":"Identification, synthesis, and biological evaluations of potent inhibitors targeting type I protein arginine methyltransferases","volume":"62","author":"Li","year":"2022","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2026.118699_bb0705","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.tig.2020.07.011","article-title":"Mammalian SWI\/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies","volume":"36","author":"Centore","year":"2020","journal-title":"Trends Genet"},{"key":"10.1016\/j.bmc.2026.118699_bb0710","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/epigenomes6010010","article-title":"SWI\/SNF chromatin remodeling enzymes in melanoma","volume":"6","author":"Dreier","year":"2022","journal-title":"Epigenomes"},{"key":"10.1016\/j.bmc.2026.118699_bb0715","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1073\/pnas.1316793111","article-title":"Functional epigenetics approach identifies BRM\/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers","volume":"111","author":"Hoffman","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2026.118699_bb0720","doi-asserted-by":"crossref","first-page":"10761","DOI":"10.1021\/acs.jmedchem.3c00953","article-title":"Discovery of SMD-3040 as a potent and selective SMARCA2 PROTAC degrader with strong in vivo antitumor activity","volume":"66","author":"Yang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0725","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1021\/acs.jmedchem.4c02535","article-title":"Discovery of FHD-286, a first-in-class, orally bioavailable, allosteric dual inhibitor of the Brahma homologue (BRM) and Brahma-related gene 1 (BRG1) ATPase activity for the treatment of SWItch\/sucrose non-fermentable (SWI\/SNF) dependent cancers","volume":"68","author":"Vaswani","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0730","doi-asserted-by":"crossref","first-page":"S677","DOI":"10.1016\/j.annonc.2023.09.2262","article-title":"1128P a phase I dose escalation and expansion study of FHD-286, a novel BRG1\/BRM (SMARCA4\/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma","volume":"34","author":"Patel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0735","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-23-C016","article-title":"Abstract C016: evaluating clinical biomarkers of FHD-286, a potent and selective inhibitor of BRG1\/BRM, in metastatic uveal melanoma","volume":"22","author":"Wan","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118699_bb0740","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2026.118699_bb0745","doi-asserted-by":"crossref","unstructured":"G.V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, J.J. Grob, V. Chiarion-Sileni, C. Lebbe, M. Mandal\u00e0, M. Millward, A. Arance, I. Bondarenko, J.B. Haanen, J. Hansson, J. Utikal, V. Ferraresi, N. Kovalenko, P. Mohr, V. Probachai, D. Schadendorf, P. Nathan, C. Robert, A. Ribas, D.J. DeMarini, J.G. Irani, S. Swann, J.J. Legos, F. Jin, B. Mookerjee, K. Flaherty, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, Lancet, 386 (2015) 444\u2013451.","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"10.1016\/j.bmc.2026.118699_bb0750","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.3390\/cancers17111755","article-title":"Cardiovascular safety profile of BRAF and MEK inhibitors in melanoma: FAERS data through a retrospective disproportionality analysis (2014\u20132023)","volume":"17","author":"Barbieri","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2026.118699_bb0755","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118699_bb0760","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3390\/ph18060853","article-title":"Metabolic reprogramming in melanoma: an epigenetic point of view","volume":"18","author":"Giuliani","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bmc.2026.118699_bb0765","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.3390\/cancers12102870","article-title":"Tumor microenvironment: implications in melanoma resistance to targeted therapy and immunotherapy","volume":"12","author":"Falcone","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2026.118699_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218359","article-title":"Emerging biomarkers in melanoma: bridging molecular discovery and precision oncology","volume":"645","author":"Xu","year":"2026","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmc.2026.118699_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112903","article-title":"First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2\/4\/6 in vivo","volume":"209","author":"Wei","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118699_bb0780","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231519","article-title":"PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy","volume":"221","author":"Wang","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmc.2026.118699_bb0785","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1039\/C8BM01403E","article-title":"A peptide-modified solid lipid nanoparticle formulation of paclitaxel modulates immunity and outperforms dacarbazine in a murine melanoma model","volume":"7","author":"Banerjee","year":"2019","journal-title":"Biomater Sci"},{"key":"10.1016\/j.bmc.2026.118699_bb0790","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/acsbiomaterials.9b00946","article-title":"Targeted and reduction-sensitive cross-linked PLGA Nanotherapeutics for safer and enhanced chemotherapy of malignant melanoma","volume":"6","author":"Wang","year":"2020","journal-title":"ACS Biomater Sci Eng"},{"key":"10.1016\/j.bmc.2026.118699_bb0795","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2020.03.023","article-title":"Transdermal siRNA delivery by pH-switchable micelles with targeting effect suppress skin melanoma progression","volume":"322","author":"Wang","year":"2020","journal-title":"J Control Release"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:45:50Z","timestamp":1783169150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":159,"alternative-id":["S0968089626001550"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118699","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent progress in small-molecule targeted therapies for melanoma treatment","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118699"}}